Lidia Daszkiewicz

Lidia Daszkiewicz, PhD, has a diverse work experience in the field of biotechnology and immunotherapy. Lidia has held senior director and leadership positions in various organizations. Their most recent role is as a Translational Research Lead at Genmab, a biotechnology company focused on developing therapies for cancer patients. Prior to this, they served as the Senior Director of Immuno-Oncology at Crown Bioscience, where they led in vitro activities for advancing oncology and immune-mediated inflammatory diseases. Before Crown Bioscience, Lidia worked at OcellO as both Senior Director and Head of Immuno-Oncology, responsible for corporate strategy, program development, and project coordination. Lidia also had experience as an R&D Scientist/Business Developer at eTheRNA Immunotherapies, overseeing technology transition and market development for immunotherapies targeting cancer and infectious diseases. Lidia began their career as a Postdoc at the Laboratory for Molecular and Cellular Therapy, focusing on mRNA-based cancer immunotherapy research. Lidia also completed their PhD at the Spanish National Centre for Biotechnology, conducting significant projects related to T-cell homeostasis and autoimmune diseases. Additionally, they had a visiting scientist position at Genentech, where they collaborated on T-cell receptor analysis. Lidia's early career involved research assistant roles at Flanders Interuniversity Institute for Biotechnology and Uniwersytet Przyrodniczy w Lublinie, where they contributed to plant biology and applied genetics research.

Lidia Daszkiewicz, PhD, pursued their education in various institutions, specializing in the field of biotechnology, immunology, and oncology. From 2001 to 2006, they obtained a Licentiate in Biotechnology from the University of Life Sciences in Lublin, Poland. Following this, they pursued a Master's degree in Biotechnology at Ghent University from 2005 to 2006. Continuing their academic journey, they obtained a PhD in Molecular Biology from the Universidad Autónoma de Madrid, specializing in Immunology and Oncology, from 2007 to 2012. In 2019, they participated in the Talent Accelerator Programme for BioBusiness (TAP BioBusiness).